LEARNING OBJECTIVES
After completing this journal-based CME activity, participants will be able to:
■ List the revisions included in the 2009 FIGO staging system for endometrial cancer.
■ Describe the appearance of endometrial cancer at MR imaging.
■ Discuss the use of diffusion-weighted and dynamic contrast-enhanced MR imaging for endometrial cancer staging.
Introduction
Endometrial cancer is the fourth most common malignancy in females and the most common malignancy of the female reproductive tract (1) . There were an estimated 43,470 new cases and approximately 7950 deaths from endometrial cancer in the United States in 2010 (2) . The prevalence of endometrial cancer is increasing due to an aging population combined with rising levels of obesity (3) . Approximately 75% of cases occur in postmenopausal women, with the median age at diagnosis being 70 years. Adenocarcinomas account for 90% of endometrial neoplasms, whereas uterine sarcomas are relatively rare and account for only 2%-6%; the remaining histologic types include adenocarcinoma with squamous cell differentiation and adenosquamous carcinoma (4, 5) . Endometrial cancer is staged with the International Federation of Gynecology and Obstetrics (FIGO) system, which recently underwent a major revision (6) . Prognosis depends on a number of factors, including stage, depth of myometrial invasion, lymphovascular invasion, histologic grade, and nodal status. Depth of myometrial invasion is the most important morphologic prognostic factor, correlating with tumor grade, presence of lymph node metastases, and overall patient survival. The prevalence of lymph node metastases increases from 3% with superficial myometrial invasion to 46% with deep myometrial invasion (7, 8) . Consequently, preoperative information about depth of myometrial invasion and histologic grade is essential in tailoring the surgical approach for these patients. Magnetic resonance (MR) imaging can accurately help assess the depth of myometrial invasion, whereas histologic grade can be determined with endometrial sampling. This information allows the selection of patients for pelvic or paraaortic lymph node sampling while obviating radical surgery in patients with a low risk of recurrent disease or significant comorbidities. Lymphadenectomy for early-stage (stage I) endometrial cancer remains controversial. Two large prospective multicenter studies investigated whether pelvic lymphadenectomy could improve the survival of women with early-stage endometrial cancer. Both studies reported no benefit in overall or recurrence-free survival in the patients randomized to lymphadenectomy (9, 10) . The recent SEPAL study (survival effect of paraaortic lymphadenectomy in endometrial cancer) showed that pelvic and paraaortic lymphadenectomy improves outcome in patients with an intermediate or high risk of recurrent disease (11) . The authors of this study acknowledged that MR imaging findings are an important predictor of lymph node metastases and, when combined with tumor grade and histologic findings, could be useful in selecting patients at low risk for recurrence (11) . MR imaging can also allow accurate assessment of more advanced disease such as cervical stromal invasion or adnexal involvement. Additional information from an MR imaging staging examination (eg, uterine size, tumor volume, presence of ascites or adnexal disease) may help determine whether the surgical approach should be transabdominal, transvaginal, or laparoscopic.
Diffusion-weighted and dynamic multiphase contrast medium-enhanced MR imaging sequences have been shown to improve the accuracy of MR imaging in assessing the depth of myometrial invasion and can be used to assess tumor response to therapy and to differentiate tumor recurrence from posttreatment changes (12) (13) (14) . In this article, we discuss the MR imaging assessment of endometrial cancer in terms of imaging protocol, recent modifications to the FIGO staging system, imaging appearances, and the complementary roles of diffusion-weighted and dynamic contrast-enhanced MR imaging.
MR Imaging Protocol
The patient should void approximately 1 hour before the examination to ensure that the bladder is only partially filled, since a full bladder may degrade T2-weighted MR images (5) . An antiperistaltic agent such as hyoscine butyl bromide or glucagon is administered to reduce artifact from small bowel peristalsis. Alternatively, the patient can fast for 4-6 hours before the procedure, although in our experience, almost all patients require an antiperistaltic agent, even if they have been fasting (5) . At our institution, the MR imaging studies are performed on a 1.5-T magnet (Signa Excite; GE Healthcare, Waukesha, Wis) with an eight-channel cardiac array coil. All imaging is performed with the patient supine. Axial, axial oblique, and sagittal fast recovery fast spinecho T2-weighted images and axial T1-weighted images of the pelvis are obtained ( Table 1 ). All axial oblique images are obtained in a plane perpendicular to the endometrial cavity (5, 12, 14) . Sagittal and axial oblique diffusion-weighted MR imaging of the pelvis is performed with b values of 0, 500 (sagittal), and 800 (axial oblique) sec/ mm 2 ( Table 1) . Note.-DCE = dynamic contrast-enhanced, DW = diffusion-weighted, EP = echoplanar, FRFSE = fast recovery fast spin-echo, FSE = fast spin-echo, GRE = gradientrecalled echo, T1W = T1-weighted, T2W = T2-weighted.
*Varies
depending on required coverage.
Dynamic contrast-enhanced MR images are obtained with a three-dimensional gradientrecalled echo T1-weighted LAVA (liver acquisition volume acceleration) sequence (GE Healthcare) after the administration of 0.1 mmol/kg of gadolinium at a rate of 2 mL/sec (5, 12, 14) . Images are acquired prior to contrast medium injection and then during multiple phases of enhancement in both sagittal and axial oblique planes (sagittal: 25 sec, 1 min, and 2 min after injection; axial oblique: 4 min after injection) ( Table 1) . Dynamic contrast-enhanced MR imaging is not performed in patients with renal impairment (estimated glomerular filtration rate <30). If advanced disease is suspected, axial imaging of the abdomen is also performed from the lung bases to the aortic bifurcation to assess for lymphadenopathy using a FIESTA (axial fast imaging employing steady-state acquisition [GE Medical Systems, Milwaukee, Wis]) or halfFourier RARE (rapid acquisition with relaxation enhancement) sequence. 
FIGO Staging System
Surgical staging of endometrial cancer was first proposed in 1988, and the staging system was updated in 2009 (Table 2) (Fig 3) . Stage II tumors were previously subdivided into stage IIA and IIB tumors, with IIA tumors characterized by endocervical glandular invasion and IIB tumors by cervical stromal invasion. The new system no longer has subsets IIA and IIB. Instead, tumors with endocervical glandular invasion are now considered stage I tumors, and tumors with cervical stromal invasion are defined as stage II tumors (Fig 6) . Stage III is still composed of three subdivisions: IIIA, IIIB, and IIIC. Stage IIIA tumors invade the serosa or adnexa (Fig 7) , and stage IIIB tumors invade the vagina or parametrium (Fig 8) . Previously, stage IIIC referred to any lymphadenopathy (pelvic or retroperitoneal); in the new FIGO system, however, stage IIIC is divided into stage IIIC1 (Fig 9) , which is characterized by pelvic lymph node involvement, and stage IIIC2 (Fig 10) , which is characterized by paraaortic lymph node involvement. These changes reflect prognostic data that suggest a worse outcome in patients with involvement of paraaortic nodes than in those with involvement of pelvic nodes only (18) . Stage IV remains unchanged: Stage IVA tumors (Fig 11) extend into adjacent bladder or bowel, and stage IVB tumors have distant metastases (eg, to the liver or lungs). 
MR Imaging Appearances
Endometrial cancer is isointense relative to hypointense normal endometrium on unenhanced T1-weighted images and most commonly shows heterogeneous intermediate signal intensity relative to hyperintense normal endometrium on T2-weighted images (Figs 1-3) (5,19-21 ). Relative to normal myometrium, the tumor is mildly hyperintense on T2-weighted images. At conventional MR imaging, the depth of myometrial invasion is optimally depicted with T2-weighted sequences. In the previous version of the FIGO staging system, breach or interruption of the junctional zone was important for differentiating between tumors confined to the endometrial complex and those invading the inner layer of the myometrium (Fig 3) .
However, this finding may become less important now that confinement to the endometrial complex and inner myometrial invasion are both classified as stage IA (Fig 3) . In postmenopausal women, there is thinning of the myometrium secondary to uterine involution, which can make accurate assessment of the depth of myometrial invasion challenging at conventional MR imaging (Fig 5)  (22,23) . Other commonly reported pitfalls in assessing the depth of myometrial invasion include tumor extension into the cornua, myometrial compression from a polypoid tumor, poor tumor-tomyometrium contrast (Fig 5) , and the presence of leiomyomas (Fig 7) or adenomyosis (14,16,20,24) . Morphologic imaging is of limited value in these cases, and the addition of diffusion-weighted and dynamic contrast-enhanced MR imaging sequences is extremely helpful in assessing the depth of myometrial invasion. The diagnostic accuracy of conventional MR imaging in this context ranges from 55% to 77% (17, 22) . Standard imaging is also significantly limited in its ability to help detect lymph node metastases. It relies on nodal size, shape, and internal architecture to help differentiate between benign and metastatic nodes, all of which features have been shown to be highly variable predictors of nodal involvement (25, 26) .
Added Value of Diffusion-weighted and Dynamic Contrast-enhanced MR Imaging
Dynamic contrast-enhanced MR imaging was first shown to improve the staging accuracy of MR imaging for endometrial cancer in the early 1990s (27) . Differential enhancement within the endometrial cavity can allow tumor to be distinguished from blood products and debris (16, 17, 27, 28) . Endometrial tumors enhance earlier than does normal endometrium after the administration of intravenous contrast medium, which aids in the detection of small tumors confined to the endometrial complex. Normal myometrium enhances intensely compared with hypointense endometrial tumor (Figs 1-6 ). Maximum contrast between hyperintense myometrium and hypointense endometrial tumor occurs 50-120 seconds after contrast medium administration, and this is the most important phase for accurate assessment of the depth of myometrial invasion (Figs 2, 6 ) (17). Delayedphase images obtained 3-4 minutes after contrast medium administration are useful in evaluating for cervical stromal invasion (FIGO stage II). The presence of an intact enhancing cervical mucosa excludes stromal invasion.
The combination of dynamic contrast-enhanced and T2-weighted MR imaging offers a "one-stop" examination for endometrial cancer staging and is recommended by the European Society for Urological Research in its guidelines for endometrial cancer staging (22) . Dynamic contrast-enhanced images, when read together with T2-weighted images, have a diagnostic accuracy of up to 98% for assessing myometrial invasion (12, 14, 16, 17, 22, (29) (30) (31) (32) (33) . However, there is some controversy in the literature regarding the added value of dynamic contrast-enhanced MR imaging for overall FIGO staging: Although the majority of published studies have shown an improvement in staging accuracy with dynamic contrast-enhanced MR imaging, some authors have found no benefit (14, 16, 17, 22, (29) (30) (31) 34, 35) .
Diffusion-weighted MR imaging is a functional imaging technique that displays information about water mobility, tissue cellularity, and the integrity of the cell membranes (36) (37) (38) . Endometrial cancer exhibits impeded diffusion compared with surrounding tissue, manifesting with high signal intensity on diffusion-weighted MR images and low signal intensity on ADC maps, which provide a quantitative measure of water diffusion (Figs 7, 8) (38-41). Diffusion-weighted MR images should always be reviewed with their corresponding ADC maps and other anatomic images to avoid pitfalls such as T2 shine-through (apparent high signal intensity of a lesion due to the long T2) (Fig 7) . Impeded diffusion can also occur in areas of retained mucus such as an obstructed endometrial cavity, and cross-referencing with anatomic images can help differentiate this finding from tumor. In clinical practice, diffusion-weighted MR imaging should be performed with at least two b values: a low value of 0 or 50 sec/mm 2 and a high value of 500-1000 sec/mm 2 (13, 40, 42) . The higher the b value, the less background signal and T2 shinethrough will be present on the images. We have found a high b value of 800 sec/mm 2 to be optimal and use this b value for axial oblique diffusionweighted MR imaging. We also use a third b value (500 sec/mm 2 ) for sagittal imaging in the belief that it aids in assessing myometrial invasion and cervical stromal extension.
The added value of diffusion-weighted MR imaging for endometrial cancer staging is less well established than that of dynamic contrast-enhanced MR imaging; however, the diagnostic accuracy of diffusion-weighted MR imaging for assessing myo-metrial invasion ranges from 62% to 90% (40, 41) . In a recent prospective study by Rechichi et al (13) , the staging accuracy of diffusion-weighted MR imaging was superior to that of dynamic contrast-enhanced MR imaging and had a higher level of interobserver agreement. The authors suggested that diffusion-weighted MR imaging could replace dynamic contrast-enhanced MR imaging for endometrial cancer staging, offering the potential advantages of reduced scanning time and obviation of the intravenous administration of gadolinium-based contrast medium (Fig 8) (13) . Diffusion-weighted imaging can also provide quantitative information in the form of ADC values. For calculation of ADC values, six or more b values should be used to ensure accurate quantification of impeded diffusion (42) . Malignant tumors have significantly lower ADC values than benign lesions such as endometrial polyps and submucosal leiomyomas (39) . Caution must be used because tumor necrosis in poorly differentiated lesions may also have high ADC values (38, 41) .
Impeded diffusion can occur in any normal anatomic structure with a high cellular density. Reactive lymph nodes may have high signal intensity at diffusion-weighted MR imaging due to their high cellular density, and impeded diffusion has been reported in both benign and metastatic lymph nodes (12, 42) . There are conflicting reports in the literature regarding the detection of lymph node metastases at diffusion-weighted MR imaging of gynecologic malignancies. Lin et al (43) demonstrated that 3.0-T MR imaging had a greater sensitivity in the detection of nodal metastases in patients with endometrial and cervical cancer. The authors reported that ADC values for malignant nodes were significantly lower than those for benign nodes, and that the use of nodal ADC values combined with lymph node size yielded a sensitivity of 83% for assessing the presence of nodal malignancy (43) . In contrast, Nakai et al (44) used 1.5-T MR imaging to evaluate nodal ADC values in gynecologic malignancies and were unable to differentiate benign from malignant lymph nodes. However, they did find that diffusion-weighted MR imaging was useful in the detection of lymph nodes.
Conclusions
Significant changes have been made to the 2009 FIGO staging system for endometrial cancer, which has important implications for radiologists. Key changes include simplification of stage I disease and removal of cervical mucosal invasion as a distinct stage. Diffusion-weighted and dynamic contrast-enhanced MR imaging are useful adjuncts to standard morphologic imaging and may improve overall staging accuracy.
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